Medical Condition News

RSS

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012

BHD launches Statin Induced Myopathy Genotype test

Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation.

31 May 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

DHA prevents age-related vision loss in lab tests

An omega-3 fatty acid found in fish, known as DHA, prevented age-related vision loss in lab tests, demonstrates recently published medical research from the University of Alberta.

31 May 2012

Genetics can predict success of smoking cessation and need for medications

Genetics can help determine whether a person is likely to quit smoking on his or her own or need medication to improve the chances of success, according to research published in today's American Journal of Psychiatry. Researchers say the study moves health care providers a step closer to one day providing more individualized treatment plans to help patients quit smoking.

31 May 2012

TAU researcher develops new antibodies to target and destroy cancer cells

Because cancer cells grow very quickly, chemotherapy is designed to target cells whose numbers grow rapidly. But this treatment comes with a heavy price - many healthy cells essential for body functions are also targeted and killed by the toxin. This dangerous side-effect has prompted researchers to seek better and more selective ways to kill cancer cells inside the body.

31 May 2012

Pfizer’s XALKORI now available in Canada

Pfizer Canada is pleased to announce that XALKORI (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).

31 May 2012

Study shows how tafamidis drug works against amyloid disease

Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works.

31 May 2012

U.S. FDA clears INJEX Pharma’s needle free injection system

The FDA had registered INJEX Pharma GmbH, Berlin, and INJEX Pharma US, Miami, and given approval for the import and sale of INJEX 30 in the US market. The condition was the registration by the FDA for INJEX Pharma GmbH as manufacturer and exporter.

31 May 2012

International conference: 'Preventing Overdiagnosis'

Overdiagnosis poses a significant threat to human health by labeling healthy people as sick and wasting resources on unnecessary care, warns Ray Moynihan, Senior Research Fellow at Bond University in Australia, in a feature published on bmj.com today.

31 May 2012

Miracor receives three new U.S. patents for novel PICSO system to treat STEMI

Miracor Medical Systems announced today that it has been granted three new U.S. patents covering a unique dual balloon method and the new "Wien Algorithm" of its novel PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system that ensures a stable and repeatable PICSO treatment designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty).

31 May 2012

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

31 May 2012

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

Acorda Therapeutics, Inc., makers of Ampyra (dalfampridine), today announced the launch of Ampyra Dialogues, the first-ever online talk show where patients and medical experts talk about how walking problems affect people living with MS.

31 May 2012

Beyond chemotherapy to cure leukemia

The fight against cancer is not won in a single battle: long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear.

30 May 2012

New technique promotes dramatic increase in cardiac function

LoneStar Heart Inc., today announced the advancement of a new therapeutic strategy aimed at genetic reprogramming of cardiac fibroblasts into functioning heart muscle cells to treat damage following a heart attack and other forms of heart disease.

30 May 2012

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

30 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

IACFS/ME releases new guidelines for chronic fatigue syndrome

The International Association for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (IACFS/ME), the largest group of physicians and researchers dedicated to chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), has released updated care guidelines directed at primary care physicians and other health care providers.

30 May 2012

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

Physicians and researchers at John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 cancer centers, will present the latest findings in blood-cancer research at the 2012 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1-5. Their involvement in these studies is part of John Theurer Cancer Center's continued focus to bolster its research program.

30 May 2012

Sequenom MassARRAY System detects EML4/ALK fusion gene in NSCLC

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ALK in non-small cell lung cancer.

30 May 2012